Bristol-Myers Squibb Company (BMY) 49.34 $BMY
Is Now a Good Time to Buy Bristol Myers?
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 1 min ago
Bristol-Myers updated investors on its prolific research program for the cancer drug nivolumab this week. The news came in a flurry Wednesday, beginning with a new combination study planned with Celldex , and culminating with updated data for...
Midday Glance: Pharmaceuticals companies
AP - Mon May 19, 12:21PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Post Earnings Update: Bristol-Myers Squibb Has Sunk 1.1% Lower in Past 2 Weeks (BMY)
Comtex SmarTrend(R) - Mon May 19, 11:24AM CDT
When Bristol-Myers Squibb (NYSE:BMY) reported earnings 20 days ago on April 29th, 2014, analysts, on average, expected the company to report earnings of $0.43 on sales of $3.9 billion. Bristol-Myers Squibb actually reported earnings of $0.46 per share on sales of $3.8 billion, beating EPS estimates by $0.03 and missing revenue estimates by $78.3 million. Since the company's report, shares of Bristol-Myers Squibb have fallen from $49.32 to $48.78, representing a loss of 1.1% in the past 20 days.
Early Glance: Pharmaceuticals companies
AP - Mon May 19, 9:37AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
FDA to give blood cancer drug faster review
By The Associated Press - AP - Mon May 19, 8:58AM CDT
A potential blood cancer treatment from drugmakers AbbVie and Bristol-Myers Squibb has been named a "breakthrough therapy" by the Food and Drug Administration, a designation designed to speed up the drug's testing and approval process.
Academic and Pharmaceutical Leaders Meet at the ALS Therapy Development Institute to Discuss Biomarkers in ALS
PRWeb - Mon May 19, 8:13AM CDT
The ALS Therapy Development Institute (ALS TDI) announced today that it is hosting a meeting on-site with leaders in academia and Pharma to discuss biomarkers in ALS. The meeting, held in collaboration with The ALS Association (ALSA), brings together 24 leaders from various academic institutions and pharmaceutical companies, including Genentech, Pfizer, Astra Zeneca, Biogen Idec, Bristol-Myers Squibb, Iron Horse Diagnostics, Inc., University of Massachusetts Medical School, Massachusetts General Hospital, SUNY Upstate Medical University, Barrow Neurological Institute, Voyager Therapeutics, The Michael J. Fox Foundation for Parkinson's Research, Weiner Laboratory, Northeast ALS Consortium, National Institute of Neurological Disorders and Stroke (NINDS), ALSA and ALS TDI.
Bristol-Myers Squibb and AbbVie Receive U.S. FDA Breakthrough Therapy Designation for Elotuzumab, an Investigational Humanized Monoclonal Antibody for Multiple Myeloma
Business Wire - Mon May 19, 7:01AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies. The designation is based on findings from a randomized Phase 2, open-label study that evaluated two dose levels of elotuzumab in combination with lenalidomide and low-dose dexamethasone in previously-treated patients, including the 10 mg/kg dose that is being studied in Phase 3 trials. Data from the Phase 2 trial were most recently presented at the 18th Annual Congress of the European Hematology Association (EHA) in 2013 (click here to view press release).
Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - Mon May 19, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and
Biotech of the Week: Ariad Pharmaceuticals, Inc.
Brian Orelli, The Motley Fool - Motley Fool - Sun May 18, 5:30PM CDT
Ariad Pharmaceuticals is the biotech of the week on the Fool's weekly biotech-focused show, Biotech Banter . Shares of the biotech have been on a bit of a roller coaster over the last year as investors went from having high hopes for Ariad...
Final Glance: Pharmaceuticals companies
AP - Fri May 16, 5:06PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
TogoRun Named "International Agency Of The Year" At The 2014 PRWeek Global Awards
PR Newswire - Fri May 16, 1:43PM CDT
TogoRun (www.togorun.com), a global health and well-being communications and public affairs agency, was named International Agency of the Year at the inaugural PRWeek Global Awards ceremony last night in Barcelona, Spain. The agency was also named winner in the Corporate Social Responsibility category for PATH B (Patients and Professionals Acting Together for Hepatitis
, a hepatitis B patient and professional engagement and education program developed for Bristol-Myers Squibb.
ASCO 2014: Making and Breaking Cancer Drugs
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri May 16, 1:30PM CDT
As oncology has become the hottest space within pharmaceuticals and biotech, the annual American Society of Clinical Oncology (ASCO) is pretty much now the Super Bowl for companies in this space. Meetings like ASCO certainly do lead to companies...
Today's Top Health Care Stocks to Watch: Bristol-Myers Squibb and Kamada Ltd.
George Budwell, The Motley Fool - Motley Fool - Fri May 16, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Bristol-Myers Squibb , Shares of Bristol-Myers Squibb fell over 6% yesterday following a downgrade by BMO Capital Markets after the company reported weak...
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
Business Wire - Fri May 16, 7:00AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference on Monday, June 2, 2014, at 8 a.m. EDT (7 a.m. CDT) to review data presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Company executives will provide an overview of data presented at the meeting, with a focus on the company's immuno-oncology portfolio, and address inquiries from investors and analysts.
Why the National Bank of Greece, Alliant Techsystems Inc., and Bristol-Myers Squibb Co Are Today's 3
Dan Carroll, The Motley Fool - Motley Fool - Thu May 15, 6:00PM CDT
Where'd the gains go? That's what investors were left asking themselves after today's market plunge. The S&P 500 nosedived by 0.9% on a day marked by red across most industries. Three stocks suffered steep downturns, however, as the National...
Bristol-Myers downgraded
at Investor's Business Daily - Thu May 15, 5:39PM CDT
The big pharma was downgraded to market perform from outperform by BMO Capital Markets. Its price target was cut to 55 from 65 after phase-2 data on Bristol- Myers' (BMY) immuno-oncology candidate was released Wed. The drug, nivolumab, is used in...
Pipeline Breakdown: Merck & Co. Inc.
Brian Orelli, The Motley Fool - Motley Fool - Thu May 15, 5:30PM CDT
Merck recently held its analyst day, updating analysts and investors listening in on its pipeline. While there weren't any major announcements -- no high-profile clinical trial results were announced -- there were a few tidbits that investors...
Most active New York Stock Exchange-traded stocks
AP - Thu May 15, 5:15PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Is Now a Good Time to Buy Bristol Myers?
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 1 min ago
Bristol-Myers updated investors on its prolific research program for the cancer drug nivolumab this week. The news came in a flurry Wednesday, beginning with a new combination study planned with Celldex , and culminating with updated data for...
Midday Glance: Pharmaceuticals companies
AP - Mon May 19, 12:21PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Post Earnings Update: Bristol-Myers Squibb Has Sunk 1.1% Lower in Past 2 Weeks (BMY)
Comtex SmarTrend(R) - Mon May 19, 11:24AM CDT
When Bristol-Myers Squibb (NYSE:BMY) reported earnings 20 days ago on April 29th, 2014, analysts, on average, expected the company to report earnings of $0.43 on sales of $3.9 billion. Bristol-Myers Squibb actually reported earnings of $0.46 per share on sales of $3.8 billion, beating EPS estimates by $0.03 and missing revenue estimates by $78.3 million. Since the company's report, shares of Bristol-Myers Squibb have fallen from $49.32 to $48.78, representing a loss of 1.1% in the past 20 days.
Early Glance: Pharmaceuticals companies
AP - Mon May 19, 9:37AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
FDA to give blood cancer drug faster review
By The Associated Press - AP - Mon May 19, 8:58AM CDT
A potential blood cancer treatment from drugmakers AbbVie and Bristol-Myers Squibb has been named a "breakthrough therapy" by the Food and Drug Administration, a designation designed to speed up the drug's testing and approval process.
Academic and Pharmaceutical Leaders Meet at the ALS Therapy Development Institute to Discuss Biomarkers in ALS
PRWeb - Mon May 19, 8:13AM CDT
The ALS Therapy Development Institute (ALS TDI) announced today that it is hosting a meeting on-site with leaders in academia and Pharma to discuss biomarkers in ALS. The meeting, held in collaboration with The ALS Association (ALSA), brings together 24 leaders from various academic institutions and pharmaceutical companies, including Genentech, Pfizer, Astra Zeneca, Biogen Idec, Bristol-Myers Squibb, Iron Horse Diagnostics, Inc., University of Massachusetts Medical School, Massachusetts General Hospital, SUNY Upstate Medical University, Barrow Neurological Institute, Voyager Therapeutics, The Michael J. Fox Foundation for Parkinson's Research, Weiner Laboratory, Northeast ALS Consortium, National Institute of Neurological Disorders and Stroke (NINDS), ALSA and ALS TDI.
Bristol-Myers Squibb and AbbVie Receive U.S. FDA Breakthrough Therapy Designation for Elotuzumab, an Investigational Humanized Monoclonal Antibody for Multiple Myeloma
Business Wire - Mon May 19, 7:01AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies. The designation is based on findings from a randomized Phase 2, open-label study that evaluated two dose levels of elotuzumab in combination with lenalidomide and low-dose dexamethasone in previously-treated patients, including the 10 mg/kg dose that is being studied in Phase 3 trials. Data from the Phase 2 trial were most recently presented at the 18th Annual Congress of the European Hematology Association (EHA) in 2013 (click here to view press release).
Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - Mon May 19, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and
Biotech of the Week: Ariad Pharmaceuticals, Inc.
Brian Orelli, The Motley Fool - Motley Fool - Sun May 18, 5:30PM CDT
Ariad Pharmaceuticals is the biotech of the week on the Fool's weekly biotech-focused show, Biotech Banter . Shares of the biotech have been on a bit of a roller coaster over the last year as investors went from having high hopes for Ariad...
Final Glance: Pharmaceuticals companies
AP - Fri May 16, 5:06PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
TogoRun Named "International Agency Of The Year" At The 2014 PRWeek Global Awards
PR Newswire - Fri May 16, 1:43PM CDT
TogoRun (www.togorun.com), a global health and well-being communications and public affairs agency, was named International Agency of the Year at the inaugural PRWeek Global Awards ceremony last night in Barcelona, Spain. The agency was also named winner in the Corporate Social Responsibility category for PATH B (Patients and Professionals Acting Together for Hepatitis
, a hepatitis B patient and professional engagement and education program developed for Bristol-Myers Squibb. ASCO 2014: Making and Breaking Cancer Drugs
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri May 16, 1:30PM CDT
As oncology has become the hottest space within pharmaceuticals and biotech, the annual American Society of Clinical Oncology (ASCO) is pretty much now the Super Bowl for companies in this space. Meetings like ASCO certainly do lead to companies...
Today's Top Health Care Stocks to Watch: Bristol-Myers Squibb and Kamada Ltd.
George Budwell, The Motley Fool - Motley Fool - Fri May 16, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Bristol-Myers Squibb , Shares of Bristol-Myers Squibb fell over 6% yesterday following a downgrade by BMO Capital Markets after the company reported weak...
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
Business Wire - Fri May 16, 7:00AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference on Monday, June 2, 2014, at 8 a.m. EDT (7 a.m. CDT) to review data presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Company executives will provide an overview of data presented at the meeting, with a focus on the company's immuno-oncology portfolio, and address inquiries from investors and analysts.
Why the National Bank of Greece, Alliant Techsystems Inc., and Bristol-Myers Squibb Co Are Today's 3
Dan Carroll, The Motley Fool - Motley Fool - Thu May 15, 6:00PM CDT
Where'd the gains go? That's what investors were left asking themselves after today's market plunge. The S&P 500 nosedived by 0.9% on a day marked by red across most industries. Three stocks suffered steep downturns, however, as the National...
Bristol-Myers downgraded
at Investor's Business Daily - Thu May 15, 5:39PM CDT
The big pharma was downgraded to market perform from outperform by BMO Capital Markets. Its price target was cut to 55 from 65 after phase-2 data on Bristol- Myers' (BMY) immuno-oncology candidate was released Wed. The drug, nivolumab, is used in...
Pipeline Breakdown: Merck & Co. Inc.
Brian Orelli, The Motley Fool - Motley Fool - Thu May 15, 5:30PM CDT
Merck recently held its analyst day, updating analysts and investors listening in on its pipeline. While there weren't any major announcements -- no high-profile clinical trial results were announced -- there were a few tidbits that investors...
Most active New York Stock Exchange-traded stocks
AP - Thu May 15, 5:15PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
